Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | PAK4 | O96013 | 3/20 | 0.41 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.41 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 2/20 | 0.38 |
| ▸ | JAK3 | P52333 | 8/20 | 0.37 |
| ▸ | TYK2 | P29597 | 6/20 | 0.37 |
| ▸ | JAK2 | O60674 | 6/20 | 0.37 |
| ▸ | JAK1 | P23458 | 4/20 | 0.37 |
| ▸ | IGF1R | P08069 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5316477 | 1.00 | NTRK1 (0.47) | NTRK1PAK4PAK1PLK4SYK | |
| SCHEMBL4513602 | 0.73 | PAK4 (0.45) | NTRK1PAK4PAK1PLK4JAK3 | |
| SCHEMBL13633931 | 0.72 | PAK4 (0.52) | NTRK1PAK4PAK1PLK4SYK | |
| SCHEMBL8243146 | 0.72 | PAK4 (0.46) | NTRK1PAK4PAK1PLK4JAK3 | |
| SCHEMBL4525983 | 0.72 | AURKA (0.47) | NTRK1PAK4PAK1PLK4JAK3 | |
| SCHEMBL5476795 | 0.72 | AURKA (0.47) | NTRK1PAK4PAK1PLK4JAK3 | |
| SCHEMBL4515170 | 0.71 | PAK4 (0.44) | NTRK1PAK4PAK1PLK4JAK2 | |
| SCHEMBL13633930 | 0.71 | PAK4 (0.44) | NTRK1PAK4PAK1PLK4JAK2 | |
| SCHEMBL4529635 | 0.70 | PAK4 (0.42) | NTRK1PAK4PAK1PLK4JAK3 | |
| SCHEMBL4524538 | 0.70 | IGF1R (0.50) | PAK4PAK1PLK4JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831216-A2 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2007-09-12 | — | — | EP | claimed |
| WO-2006067614-A2 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2006-06-29 | — | — | WO | claimed |
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | BHATTACHARYA SAMIT KUMAR | 2009-11-12 | — | — | US | disclosed |
| EP-1831216-A2 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006067614-A2 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, TP53, CCNE1 | NTRK1 4004/4885PAK4 3321/4885PAK1 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.